ClinicalTrials.gg
CompletedNCT01387555TRAVERSEUpdated Jul 8, 2026Results posted

A Phase 2b Study of Modified Vaccinia Virus to Treat Patients Advanced Liver Cancer Who Failed Sorafenib

A Phase 2 interventional study of JX-594 recombinant vaccina GM-CSF and Best Supportive Care in Hepatocellular Carcinoma, Liver Cancer and HCC, sponsored by Jennerex Biotherapeutics. Completed at 38 sites in 7 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-08.

Sponsored by Jennerex Biotherapeutics · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
129
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 926 studies in Carcinoma, Hepatocellular with a site in United States — 160 open to participants now, 245 under way, 17 of them phase 3. Carcinoma, Hepatocellular · United States.

Enrollment
156th of 775
129 · median 36
Started
2011
with 23 others
Phase 2
259 of 926
40 open now
Registered
284th of 926
by date

Among the 926 studies in Carcinoma, Hepatocellular with a site in United States, this one is the 156th largest by enrollment of the 775 interventional ones that give a count, is one of 24 that started in 2011, is one of 259 in phase 2, and was the 284th registered.

Carcinoma, Hepatocellular

3,656 studies on the registry are indexed under Carcinoma, Hepatocellular; 1,068 are open to participants now.

Browse Carcinoma, Hepatocellular studies →

Open to participants now

160 of the 926 studies in Carcinoma, Hepatocellular with a site in United States are open now. Recruiting first, the newest first:

155 more — sign in →

All 160 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 743 Carcinoma, Hepatocellular studies recruiting now, 383 (52%) set no upper age limit and 253 (34%) stop at 75 or younger; 31 take children under 18; 31 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 926 studies in Carcinoma, Hepatocellular with a site in United States, or all of them as a file.
02

Study summary

This study is to determine whether JX-594 (Pexa-Vec) plus best supportive care is more effective in improving survival than best supportive care in patients with advanced Hepatocellular Carcinoma (HCC) who have failed sorafenib.

Read the detailed description

This Phase 2b, open-label, randomized, multi-center study is designed to evaluate the efficacy and safety of JX-594 (Pexa-Vec) in patients with advanced hepatocellular carcinoma (HCC) who have previously failed sorafenib treatment. Eligible patients are randomly assigned in a 2:1 ratio to receive either the experimental therapy (JX-594 plus Best Supportive Care [BSC]) or the control therapy (BSC alone).

Patients assigned to the experimental arm receive an initial intravenous (IV) infusion of JX-594 on Day 1. This is followed by intratumoral (IT) injections of JX-594 directly into viable liver tumors under imaging guidance on Day 8, Day 22, and Weeks 6, 12, and 18. These patients will also receive BSC, but active anti-cancer treatments are strictly prohibited. In contrast, patients in the control arm receive only Best Supportive Care (e.g., hydration, nutrition, pain management) at the treating physician's discretion without any study drug injections. Experimental or active anti-cancer therapies are not permitted in the control arm.

The primary objective of this study is to compare the Overall Survival (OS) between the two treatment arms. Secondary objectives include evaluating Time-to-Tumor Progression (TTP) and objective response rate based on mRECIST criteria for HCC. The study also evaluates Time-to-Symptomatic Progression (TSP), which is defined by changes in the FACT Hepatobiliary Symptom Index (FHSI-8) questionnaire and ECOG performance status. Additionally, the study assesses changes in Quality of Life (QoL) measured by EORTC and FACT-Hep questionnaires. Finally, overall safety and tolerability are closely monitored through the incidence and severity of Adverse Events (AEs) and Serious Adverse Events (SAEs) graded according to NCI CTCAE v4.03, along with clinical laboratory evaluations.

03

Conditions studied

  • Hepatocellular Carcinoma
  • Liver Cancer
  • HCC

Keywords

  • liver cancer
  • liver tumor
  • hepatocellular cancer
  • Jennerex
  • HCC
  • Advanced HCC
  • sorafenib
  • sorafenib failure
  • sorafenib intolerant
  • Nexavar
  • Nexavar failure
  • JX594
  • oncolytic virus
  • viral therapy
  • JX
  • Biotherapeutics
  • vaccinia
  • HEP018
  • traverse
  • biologic
  • Pexa-Vec
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

KEY Inclusion Criteria:

  • Diagnosis of primary HCC by tissue (histological/cytological diagnosis), or clinical diagnosis
  • Previously treated with sorafenib for ≥ 14 days and has discontinued sorafenib treatment at least 14 days prior to randomization due to either intolerance or radiographic progression NOTE: Sorafenib is NOT required to be the most recent treatment received for HCC
  • performance status 0, 1 or 2
  • Class A; or Child-Pugh Class B7 without ascites
  • Hematocrit ≥30% or ≥10 g/dL
  • Tumor status: Measurable viable tumor in the liver and injectable under imaging-guidance; At least one tumor in the liver that has not received prior local-regional treatment OR that has exhibited >25% growth in viable tumor size since prior local-regional treatment.

KEY Exclusion Criteria:

  • Received sorafenib within 14 days prior to randomization
  • Received systemic anti-cancer therapy other than sorafenib within 28 days of randomization
  • Prior treatment with JX-594
  • count \< 50,000 PLT/ mm3
  • Total white blood cell count \< 2,000 cells/mm3
  • Prior or planned organ transplant
  • Known significant immunodeficiency due to underlying illness (e.g. /AIDS) and/or medication
  • Severe or unstable cardiac disease
  • Viable CNS associated with clinical symptoms
  • Pregnant or nursing an infant
  • History of inflammatory skin condition (e.g., eczema requiring previous treatment, atopic dermatitis)
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
129 participants (actual)

Study arms

  • Experimental
    JX-594 + Best Supportive Care

    Patients on Arm A will receive 1 e9 pfu (plaque forming units) total dose of JX-594 (Vaccinia GM-CSF / TK-deactivated Virus) on each of six (6) treatments over 18 weeks.

    Biological: JX-594 recombinant vaccina GM-CSF

  • Other
    Best Supportive Care

    Patients on the control arm (Arm B) will have best supportive care over 18 weeks.

    Other: Best Supportive Care

Interventions

  • BiologicalJX-594Studies of JX-594JX-594 pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Patients will be randomised 2:1 to Arm A or Arm B and will receive 6 treatments on days 1, 8, 22, week 6, week 12, and week 18 plus best supportive care as needed.

  • OtherBest Supportive Care

    Patients will be randomised 2:1 to Arm A or Arm B and will receive best supportive care as needed.

06

What researchers measure

Primary outcomes

  1. Survival

    Determine overall survival for patients receiving JX-594 plus best supportive care (Arm A) compared with those patients receiving best supportive care (Arm B) in patients with advanced hepatocellular carcinoma (HCC) who have failed sorafenib treatment.

    Time frame: From randomization until death from any cause, assessed up to 21 months.

Secondary outcomes

  1. Time to Tumor Progression

    Determine time-to-tumor-progression (TTP) for JX-594 + BSC compared with BSC alone based on mRECIST for HCC. Progression is defined as 2 consecutive time points with increases in the sum of the longest diameters (SLD) of viable target tumors of at least 20% for each time point.

    Time frame: CT scan every six weeks until progression or death, assessed up to 21 months

  2. Mean Percent Change From Baseline in Quality of Life (FACT-Hep Score)

    Change in Quality of Life (QoL) over time based on the physical well-being and additional concerns domains of the Functional Assessment of Cancer Therapy - Hepatobiliary (FACT-Hep) Questionnaire. The FACT-Hep measures health-related quality of life in patients with hepatobiliary cancer. The item scores from these specific subscales are summed to compute a combined score. The combined score ranges from 0 to 100. Higher scores represent a better quality of life and a better outcome.

    Time frame: Baseline to Visit 8 (Week 6 ) and Visit 11 (Week 12)

  3. Overall Disease Control Rate (Tumor Response)

    The overall disease control rate is defined as the percentage of patients achieving a Complete Response (CR), Partial Response (PR), or Stable Disease (SD) based on modified Response Evaluation Criteria in Solid Tumors (mRECIST) for Hepatocellular Carcinoma (HCC). Per mRECIST for HCC, CR is the disappearance of any intratumoral arterial enhancement in all target lesions; PR is a \>=30% decrease in the sum of the longest diameters (SLD) of viable target lesions; and SD is disease that does not qualify for either PR or progressive disease. Best response over all time points after Baseline was used.

    Time frame: CT scan every 6 weeks until progression or death, assessed up to 21 months

  4. Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)

    Safety will be assessed by the number of adverse events (AEs) and serious adverse events (SAEs)

    Time frame: Up to 28 days after the last dose of study drug, assessed up to 14 months.

  5. Time-to-symptomatic-progression

    Symptomatic progression is defined as a decrease of 4 points or more from Baseline in the FHSI-8 questionnaire (that was confirmed 3 weeks later), or a decrease in ECOG performance status to 4, or death.

    Time frame: From randomization until symptomatic progression or death, assessed up to 21 months

07

Results

Posted Jul 8, 2026

Participant flow

Patients with advanced hepatocellular carcinoma (HCC) who had failed prior sorafenib treatment were recruited at 40 study centers across 7 countries (Canada, France, Germany, Hong Kong, South Korea, Taiwan, and the United States) between October 2011 and October 2013.

Participant flow — Overall Study
MilestoneJX-594 + Best Supportive CareBest Supportive Care
Started8643
Completed113
Not completed7540
Withdrew: Withdrawal by subject827
Withdrew: Adverse event134
Withdrew: Physician decision223
Withdrew: Death102
Withdrew: Protocol violation01
Withdrew: Other unspecified reasons142
Withdrew: Intercurrent illness81

Outcome measures

PrimarySurvival

Determine overall survival for patients receiving JX-594 plus best supportive care (Arm A) compared with those patients receiving best supportive care (Arm B) in patients with advanced hepatocellular carcinoma (HCC) who have failed sorafenib treatment.

Time frame:
From randomization until death from any cause, assessed up to 21 months.
Reported as:
Median · months
Survival
monthsJX-594 + Best Supportive CareBest Supportive Care
Survival4.2 (3.3 to 5.4)4.4 (3.2 to 6.0)
Statistical analysis
  • JX-594 + Best Supportive Care vs Best Supportive Care · Log Rank · p = 0.426 · Hazard ratio (hr): 1.19 · 95% CI 0.78 to 1.80Based on a stratified Cox regression model.
SecondaryTime to Tumor Progression

Determine time-to-tumor-progression (TTP) for JX-594 + BSC compared with BSC alone based on mRECIST for HCC. Progression is defined as 2 consecutive time points with increases in the sum of the longest diameters (SLD) of viable target tumors of at least 20% for each time point.

Time frame:
CT scan every six weeks until progression or death, assessed up to 21 months
Reported as:
Median · months
Time to Tumor Progression
monthsJX-594 + Best Supportive CareBest Supportive Care
Time to Tumor Progression1.8 (1.5 to 2.8)2.8 (1.5 to NA)
Statistical analysis
  • JX-594 + Best Supportive Care vs Best Supportive Care · Log Rank · p = 0.463 · Hazard ratio (hr): 1.33 · 95% CI 0.61 to 2.90Stratified Cox regression model.
SecondaryMean Percent Change From Baseline in Quality of Life (FACT-Hep Score)

Change in Quality of Life (QoL) over time based on the physical well-being and additional concerns domains of the Functional Assessment of Cancer Therapy - Hepatobiliary (FACT-Hep) Questionnaire. The FACT-Hep measures health-related quality of life in patients with hepatobiliary cancer. The item scores from these specific subscales are summed to compute a combined score. The combined score ranges from 0 to 100. Higher scores represent a better quality of life and a better outcome.

Time frame:
Baseline to Visit 8 (Week 6 ) and Visit 11 (Week 12)
Reported as:
Mean · Percent change (%)
Mean Percent Change From Baseline in Quality of Life (FACT-Hep Score)
Percent change (%)JX-594 + Best Supportive CareBest Supportive Care
Visit 8 (Week 6)-10.2 ± 18.2510.4 ± 50.88
Visit 11 (Week 12)-5.4 ± 20.15-3.6 ± 30.03
SecondaryOverall Disease Control Rate (Tumor Response)

The overall disease control rate is defined as the percentage of patients achieving a Complete Response (CR), Partial Response (PR), or Stable Disease (SD) based on modified Response Evaluation Criteria in Solid Tumors (mRECIST) for Hepatocellular Carcinoma (HCC). Per mRECIST for HCC, CR is the disappearance of any intratumoral arterial enhancement in all target lesions; PR is a \>=30% decrease in the sum of the longest diameters (SLD) of viable target lesions; and SD is disease that does not qualify for either PR or progressive disease. Best response over all time points after Baseline was used.

Time frame:
CT scan every 6 weeks until progression or death, assessed up to 21 months
Reported as:
Number · Percentage (%)
Overall Disease Control Rate (Tumor Response)
Percentage (%)JX-594 + Best Supportive CareBest Supportive Care
Overall Disease Control Rate (Tumor Response)13 (7 to 22)19 (8 to 33)
Statistical analysis
  • JX-594 + Best Supportive Care vs Best Supportive Care · Cochran-Mantel-Haenszel · p = 0.349 · Risk difference (rd): -0.06 · 95% CI -0.19 to 0.08Based on normal approximation method.
SecondaryNumber of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)

Safety will be assessed by the number of adverse events (AEs) and serious adverse events (SAEs)

Time frame:
Up to 28 days after the last dose of study drug, assessed up to 14 months.
Reported as:
Number · participants
Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
participantsJX-594 + Best Supportive CareBest Supportive Care
Patients with at least one Adverse Event (AE)8421
Patients with at least one Serious Adverse Event (SAE)5010
SecondaryTime-to-symptomatic-progression

Symptomatic progression is defined as a decrease of 4 points or more from Baseline in the FHSI-8 questionnaire (that was confirmed 3 weeks later), or a decrease in ECOG performance status to 4, or death.

Time frame:
From randomization until symptomatic progression or death, assessed up to 21 months
Reported as:
Median · months
Time-to-symptomatic-progression
monthsJX-594 + Best Supportive CareBest Supportive Care
Time-to-symptomatic-progression2.5 (1.9 to 2.9)2.0 (1.5 to 3.5)
Statistical analysis
  • JX-594 + Best Supportive Care vs Best Supportive Care · Log Rank · p = 0.458 · Hazard ratio (hr): 0.81 · 95% CI 0.46 to 1.42Based on a stratified Cox regression model.

Adverse events

Collected over All-Cause Mortality monitored/assessed up to 21 months. Adverse Events monitored/assessed from informed consent signature through 28 days after the most recent study treatment or Week 18, assessed up to 14 months.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
JX-594 + Best Supportive Care17/86 (19.8%)50/84 (59.5%)84/84 (100%)
Best Supportive Care6/43 (14%)10/25 (40%)21/25 (84%)
Most frequent serious events
Showing 10 of 67
Most frequent serious events
EventJX-594 + Best Supportive CareBest Supportive Care
Hepatic failureHepatobiliary disorders7/842/25
PyrexiaGeneral disorders7/840/25
Abdominal painGastrointestinal disorders4/842/25
Back painMusculoskeletal and connective tissue disorders1/842/25
Gastric varices haemorrhageGastrointestinal disorders1/842/25
Malignant neoplasm progressionNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/842/25
HypotensionVascular disorders6/841/25
Oesophageal varices haemorrhageGastrointestinal disorders5/841/25
Pulmonary embolismRespiratory, thoracic and mediastinal disorders5/840/25
AstheniaGeneral disorders4/841/25
Most frequent other events
Showing 10 of 53
Most frequent other events
EventJX-594 + Best Supportive CareBest Supportive Care
PyrexiaGeneral disorders67/843/25
ChillsGeneral disorders44/841/25
Abdominal painGastrointestinal disorders32/848/25
Decreased appetiteMetabolism and nutrition disorders31/843/25
NauseaGastrointestinal disorders30/844/25
AscitesGastrointestinal disorders21/848/25
HypotensionVascular disorders24/843/25
Rash pustularInfections and infestations24/840/25
AnaemiaBlood and lymphatic system disorders22/844/25
FatigueGeneral disorders22/842/25

Baseline characteristics

Intent-to-Treat (ITT) Population

Age, Continuous
Age, Continuous(Years)JX-594 + Best Supportive CareBest Supportive CareTotal
Mean60.2 ± 10.7054.5 ± 12.1058.3 ± 11.46
Sex: Female, Male
Sex: Female, Male(Participants)JX-594 + Best Supportive CareBest Supportive CareTotal
Female141024
Male7233105
Race (NIH/OMB)
Race (NIH/OMB)(Participants)JX-594 + Best Supportive CareBest Supportive CareTotal
American Indian or Alaska Native000
Asian522678
Native Hawaiian or Other Pacific Islander000
Black or African American213
White301545
More than one race000
Unknown or Not Reported213
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)JX-594 + Best Supportive CareBest Supportive CareTotal
Hispanic or Latino325
Not Hispanic or Latino8341124
Unknown or Not Reported000
Region of Enrollment
Region of Enrollment(Participants)JX-594 + Best Supportive CareBest Supportive CareTotal
South Korea391958
United States131023
Germany13013
France7714
Canada729
Taiwan6511
China101
08

Study locations

38 sites
  • Moores University of California San Diego Cancer Center
    La Jolla, California 92093, United States
  • Chao Family Comprehensive Cancer Center
    Orange, California 92868, United States
  • California Pacific Medical Center
    San Francisco, California, United States
  • Stanford Hospital and Clinics
    Stanford, California, United States
  • University of Chicago Medical Center
    Chicago, Illinois, United States
  • Billings Clinic
    Billings, Montana, United States
  • Saint Joseph's Hospital
    Paterson, New Jersey, United States
  • Montefiore Medical Center
    The Bronx, New York, United States
  • Gabrail Cancer Center
    Canton, Ohio, United States
  • University Hospitals Case Medical Center
    Cleveland, Ohio, United States
  • The Methodist Hospital Department of Surgery
    Houston, Texas 77030, United States
  • University of Alberta
    Edmonton, Alberta T6G 2B7, Canada
  • University of British Columbia
    Vancouver, British Columbia, Canada
  • Juravinski Cancer Centre
    Hamilton, Ontario, Canada
  • Ottawa Hopsital Research Institute
    Ottawa, Ontario, Canada
  • Hôpitaux Universitaires de Strasbourg - Hôpital Civil
    Strasbourg, Alsace 67091, France
  • Centre Hospitalier Universitaire Hôpital Saint André
    Bordeaux, Aquitaine 33000, France
  • Hôpital de la Croix Rousse
    Lyon, Auvergne-Rhône-Alpes 69317, France
  • CHU d'Estaing
    Clermont-Ferrand, Auvergne 63003, France
  • Hôpital Purpan
    Toulouse, Midi-Pyrenees 31059, France
  • Hôpital Saint Antoine, CPP Ile de France V
    Paris, Île-de-France Region 75571, France
  • Klinikum Rechts der Isar der Technischen Universität München
    München, Bavaria 81675, Germany
  • Medizinische Hochschule Hannover
    Hanover, Lower Saxony 30625, Germany
  • Johannes Gutenberg-Universität Mainz
    Mainz, Rhineland-Palatinate 55131, Germany
  • Universitätsklinikum Hamburg-Eppendorf
    Hamburg, 20246, Germany
  • Queen Mary Hospital
    Hong Kong, Hong Kong
  • Korea University Ansan Hospital
    Ansan-si, Gyeonggi-do 425-707, South Korea
  • Kyungpook National University Hospital
    Daegu, South Korea
  • Pusan National University Hospital
    Pusan, South Korea
  • Asan Medical Center
    Seoul, 138-736, South Korea
  • Korea University Guro Hospital
    Seoul, South Korea
  • Samsung Medical Center
    Seoul, South Korea
  • Seoul National University Hospital
    Seoul, South Korea
  • Severance Hospital,Yonsei University Health System
    Seoul, South Korea
  • Pusan National University Yangsan Hospital
    Yangsan, South Korea
  • National Cheng-Kung University Hospital
    Tainan, Taiwan
  • National Taiwan University Hospital
    Taipei, Taiwan
  • Taipei Veterans General Hospital
    Taipei, Taiwan
09

References and documents

Publications

  • Moehler M, Heo J, Lee HC, Tak WY, Chao Y, Paik SW, Yim HJ, Byun KS, Baron A, Ungerechts G, Jonker D, Ruo L, Cho M, Kaubisch A, Wege H, Merle P, Ebert O, Habersetzer F, Blanc JF, Rosmorduc O, Lencioni R, Patt R, Leen AM, Foerster F, Homerin M, Stojkowitz N, Lusky M, Limacher JM, Hennequi M, Gaspar N, McFadden B, De Silva N, Shen D, Pelusio A, Kirn DH, Breitbach CJ, Burke JM. Vaccinia-based oncolytic immunotherapy Pexastimogene Devacirepvec in patients with advanced hepatocellular carcinoma after sorafenib failure: a randomized multicenter Phase IIb trial (TRAVERSE). Oncoimmunology. 2019 Jun 3;8(8):1615817. doi: 10.1080/2162402X.2019.1615817. eCollection 2019. PubMed 31413923 ↗

Related links

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2011 to primary completion in Oct 2013, 23 months.

Results were first posted in Jul 2026, 12 years 9 months after primary completion.

Of 80 industry-sponsored phase 2 interventional studies under Carcinoma, Hepatocellular, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 50. This study's 23 months is below that.

Counting every sponsor, half of 432 studies reached it within 43 months; a quarter within 30 and three quarters within 71.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 27, 2011
First posted
Jul 4, 2011
StartActual
Oct 8, 2011
Primary completionActual
Oct 1, 2013
CompletionActual
Oct 1, 2013
Results first posted
Jul 8, 2026
Last update
Jul 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 8, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01387555
Lead sponsor
Jennerex Biotherapeutics
Responsible party
Sponsor
First posted
Jul 4, 2011
Start date
Oct 8, 2011
Primary completion
Oct 1, 2013
Completion
Oct 1, 2013
Results posted
Jul 8, 2026
Last update
Jul 8, 2026

Study contacts

James Burke, MD
study director · Jennerex Biotherapeutics

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: JX-594

Start the discussion